Objective To evaluate the clinical efficacy and safety of linezolid in the treatment of drug-resistant gram-positive coccobacterial sepsis of newborn. Methods Totally 30 neonates with drug-resistant gram-positive coccobacterial sepsis were enrolled.Clinical characteristics,pathogens,efficacy and safety of linezolid were evaluated. Results 30 resistant gram-positive strains were detected.Of these,there were 22 strains methicillin resistant coagulase negative staphylococci (MRCNS),5 strains enterococcus faecom and 3 strains staphylococcus aureus.Drug sensitivity results showed that all strains were resistant to penicillin,erythromycin,ampicillin and cefazoline,but were sensitive to linezolid.Among the MRCNS,staphylococcus epidermidis accounted for 12 strains,staphylococcus haemolyticus 6 strains,staphylococcus hominis 2 strains and staptococcus cohnii 2 strains.The clinical cure rate,significant rate,improvement rate and none effective rate were 73.3%,16.7%,6.7% and 3.3%,respectively.The overall effective rate was 90%.Overall pathogen eradication rate was 96.7%.The main adverse reactions included anemia in 2 cases,diarrhea in 2 cases (diarrhea plus granulocytopenia in 1 case),and nausea in 1 case.Liver and renal function showed no influence. Conclusion Linezolid is well-tolerated and effective in the treatment of drug-resistant gram-positive coccobacterial sepsis in neonates.
Key words
linezolid /
gram-positive bacterial /
drug resistance /
neonatal sepsis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Garazzino S,Tovo PA.Clinical experience with linezolid in infants and children[J].J Antimicrob Chemother,2011,66(S4):23-41.
[2] 中华医学会儿科学分会新生儿学组,中华医学会中华儿科杂志编辑委员会.新生儿败血症诊疗方案[J].中华儿科杂志,2003,41(12):897-899.
[3] 姜毅.新生儿败血症诊疗进展[J].中国新生儿科杂志,2010,25(2):69-72.
[4] Vardakas KZ,Kioumis I,Falagas ME.Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome[J].Curr Drug Metab,2009,10(1):2-12.
[5] Malm A,Korona-Gowniak I,Biernasiuk A,et al.Bacteriostatic or bactericidal effect of linezolid against multiresistant Streptococcus pneumoniae[J].New Microbiol,2008,31(3):363-370.
[6] Jones RN,Fritsche TR,Sader HS,et al.LEADER surveillance program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from the United States(50 medical centers)[J].Diagn Microbiol Infect Dis,2007,59(3):309-317.
[7] Kocher S,Müller W,Resch B.Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants:a systematic review[J].Int J Antimicrob Agents,2010,36(2):106-110.
[8] Deville JG,Alder S,Azimi PH,et al.Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates[J].Pediatr Infect Dis J,2003,22(S9):158-163.
[9] Clinical efficacy and tolerability of linezolid in pediatric patients:a systematic review[J].Clin Ther,2010,32(1):66-88.
PDF(323 KB)
